Loading
Latest filing published 21 Dec 2017 for Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation).
Kae-Won Yoon is a declared insider of Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation), with filings sourced from SEDI. In total, 9 filings cover trades dated from 1 June 2017 to 18 December 2017.
Every open-market trade on record is a purchase: 7 purchases worth €50k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price.
In size, the median ticket on the buying side is €5,864. None of the 7 purchases we analysed coincided with buying by another insider of the same company within 30 days.
On 21 December 2017 came the latest disclosure, an open-market purchase for €9,860 in Acerus Pharmaceuticals Corporation (formerly Trimel Pharmaceuticals Corporation). The median gap between a trade and its publication by SEDI is 3 days. The shorter that gap, the sooner other investors can see what insiders have done. These figures are compiled from regulatory filings published by SEDI. They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations